| Old Articles: <Older 23871-23880 Newer> |
|---|
 |
The Motley Fool
June 12, 2007
Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label.   |
The Motley Fool
June 12, 2007
Steven Mallas |
Take-Two's Quarter Not So Grand Take-Two Interactive posts another loss. Will a restructuring plan save the day? Investors, take note. |
The Motley Fool
June 12, 2007 |
Retail Ventures Into Trouble: Fool by Numbers The discount retail operator released first-quarter 2007 earnings: Income statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
June 12, 2007
Ryan Fuhrmann |
Foolish Forecast: Casey's Pulls Up to the Pump The convenience store operator is set to report its fourth-quarter and full-year results. Investors, here is what you can expect to see. |
The Motley Fool
June 12, 2007
Michael P. Cecil |
When Dr. Nissen Talks ... Congress and the FDA listen. The Avandia story is just beginning, and drug-safety issues were hard on the share prices of Merck when Vioxx was in the news, as well as Pfizer when torcetrapib was taken off the market. |
The Motley Fool
June 12, 2007
Tim Beyers |
Quick Take: Thanks, Dick Dick Notebaert did Denver, and Qwest investors, a great service. |
The Motley Fool
June 12, 2007
Nathan Parmelee |
Quick Take: Rexam's Clever Acquisition Buying Owens-Illinois' packaging business isn't a slam dunk, but it is an interesting move. The immediate reaction to the sale has been negative for Britain's Rexam. Investors, take note. |
The Motley Fool
June 12, 2007
Sham Gad |
Investing Lessons From Benjamin Graham Are you really investing? Or are you just speculating? Here are Benjamin Graham's three criteria for an investment and two securities that would meet his test: Trinity Industries... Mueller Water Products... |
The Motley Fool
June 12, 2007
Dave Mock |
Dueling Fools: Vonage Bear Rebuttal There are just too many cards stacked against Vonage. Investors, take note. |
The Motley Fool
June 12, 2007
Tom Taulli |
Dueling Fools: Vonage Bull Rebuttal It's definitely a true contrarian play and is not for conservative investors, but for those who like to take a flier, Vonage does have lots of potential. |
| <Older 23871-23880 Newer> Return to current articles. |
